Brought to you by 
Series B raises $114mm for Nkarta
04 Sep 2019
Executive Summary
Nkarta Therapeutics Inc. raised $114mm through its Series B round. First-time investor Samsara BioCapital led and was joined by other new investors Amgen Ventures, Deerfield Management, Life Sciences Partners, Logos Capital, and RA Capital Management, along with returning backers NEA Ventures, Novo Holdings AS, and SR One. Nkarta is developing engineered natural killer cell therapies for cancer and will use the Series B funds to support trials with NKX101, an allogenic NK cell therapy targeting NKG2D for solid and blood cancers, and IND-enabling studies with a CAR-NK project targeting CD19 for B-cell malignancies. In connection with the round, Samsara and Life Sciences Partners joined Nkarta's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B raises $114mm for Nkarta
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice